---
layout: default
title: Ropinirole Hcl
parent: 僅模型預測 (L5)
nav_order: 177
evidence_level: L5
indication_count: 0
---

# Ropinirole Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropinirole HCL: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Ropinirole HCL has been identified as a candidate drug for repurposing analysis; however, the Evidence Pack generated for this evaluation contains critical data gaps across all key assessment domains.
No predicted new indications, original indication data, mechanism of action, or UK marketing authorisation records were successfully retrieved in this pipeline run.
As a result, **a substantive repurposing assessment cannot be completed at this stage** — this report documents the current data status and the remediation steps required before evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Drug Name (INN) | Ropinirole HCL |
| Original Indication | Not retrieved (data pipeline failure) |
| Predicted New Indication | Not available — `predicted_indications` array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | **Cannot be determined** |
| UK Market Status | Not Marketed (0 MHRA authorisations retrieved) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Evaluation Cannot Proceed

The Evidence Pack for this candidate was generated with `inputs_received: []`, indicating that the upstream data pipeline did not successfully populate the core drug record prior to Evidence Pack assembly. Two blocking or high-severity data gaps have been formally logged:

| Gap ID | Category | Missing Item | Severity | Impact |
|--------|----------|-------------|----------|--------|
| DG001 | Drug Level | Regulatory warnings and contraindications | **Blocking** | Cannot complete S1 safety screening |
| DG002 | Drug Level | Mechanism of action (MOA) | High | Cannot perform mechanistic plausibility analysis |

Because `predicted_indications` is an empty array, **no TxGNN repurposing candidate has been surfaced for this drug**. Without a target indication, sections covering clinical trial evidence, literature evidence, and mechanistic rationale cannot be populated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for any predicted indication.

---

## Literature Evidence

Currently no related literature available for any predicted indication.

---

## UK Market Information

No MHRA marketing authorisations were retrieved for Ropinirole HCL in this Evidence Pack (total\_licenses: 0, market\_status: not marketed).

> **Note for reviewers:** This result is inconsistent with expected real-world data and is likely a consequence of the pipeline data failure described above. Before concluding that no UK authorisation exists, the regulatory data retrieval step should be re-run and verified against the MHRA Product Licence register and the BNF.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

> All safety fields — including key warnings, contraindications, and drug–drug interactions — returned either `[Data Gap]` or `not_found` status in this Evidence Pack. No safety data can be presented until DG001 is resolved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete: no predicted indications were generated, no original indications were retrieved, MOA data is absent, and all safety fields are empty. Proceeding to clinical feasibility review is not possible until these gaps are remediated.

**To proceed, the following is required:**

1. **Re-run the data pipeline** — `inputs_received` is empty; verify that source data files were correctly passed to the Evidence Pack generator and re-run the full pipeline for this candidate.
2. **Resolve DG001 (Blocking)** — Download and parse the MHRA SmPC / TFDA product insert PDF to extract approved warnings and contraindications; this is a prerequisite for S1 safety screening.
3. **Resolve DG002 (High)** — Query the DrugBank API (a successful hit with `result_count: 1` was logged on 2026-03-27) to retrieve the DrugBank ID, MOA, pharmacological class, and toxicity data.
4. **Confirm UK market status** — Cross-check the MHRA Product Licence register and the BNF directly to verify whether Ropinirole HCL holds any current or historical UK authorisations.
5. **Confirm DrugBank mapping** — The query log records a successful DrugBank lookup (`result_status: success`, `result_count: 1`), but `drugbank_id` remains null in the drug record. This mapping result should be retrieved and written into the Evidence Pack.
6. **Re-run TxGNN prediction** — Once original indications and DrugBank ID are confirmed, re-execute the TxGNN repurposing model to generate `predicted_indications`.
7. **Re-generate this report** once a complete Evidence Pack (v5+) is available.

---

> *This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application. YMYL Disclaimer: the content of this report must not be used to inform prescribing decisions.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

